{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:53:21Z","timestamp":1792464801109,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychogeriatrics"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>\n                    Aducanumab is a novel disease\u2010modifying anti\u2010amyloid\u2010beta (A\u03b2) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta\u2010Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid\u2010beta plaques in a time\u2010 and dose\u2010dependent manner (dose\u2013response,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and a slowed decline in cognition (22% reduction) in the high\u2010dose treated group, difference of \u22120.39 versus placebo in Clinical Dementia Rating Scale Sum Boxes (95% CI, \u22120.69 to \u22120.09;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.012) along with a reduced amyloid positron emission tomography standard uptake value ratio score (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and plasma p181\u2010tau (phosphorylated tau) level. Amyloid\u2010related imaging abnormality was reported as a serious adverse event and was profound in high\u2010dose treated group (425\/1029 in 10\u2009mg\/kg). Aducanumab has been reported to affect two main pathophysiologic hallmarks (A\u03b2 and tau) of AD. We suggest future studies addressing aducanumab's efficacy and safety to confirm that the benefit of this drug outweighs the risk.\n                  <\/jats:p>","DOI":"10.1111\/psyg.12944","type":"journal-article","created":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T20:39:05Z","timestamp":1676234345000},"page":"512-522","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Aducanumab for the treatment of Alzheimer's disease: a systematic review"],"prefix":"10.1111","volume":"23","author":[{"given":"Afroza","family":"Rahman","sequence":"first","affiliation":[{"name":"Satkhira Medical College  Satkhira Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Anwar","family":"Hossen","sequence":"additional","affiliation":[{"name":"Sheikh Sayera Khatun Medical College  Gopalganj Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Farhana Iqbal","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Sylhet MAG Osmani Medical College  Sylhet Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Bari","sequence":"additional","affiliation":[{"name":"Sher\u2010E\u2010Bangla Medical College  Barisal Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuzhat","family":"Tamanna","sequence":"additional","affiliation":[{"name":"Rangpur Medical College  Rangpur Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Salima","family":"Sultana","sequence":"additional","affiliation":[{"name":"Southern Medical College  Chittagong Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharar Naiarin","family":"Haque","sequence":"additional","affiliation":[{"name":"Dhaka Medical College  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al Masud","sequence":"additional","affiliation":[{"name":"St Louis University Hospital  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Saif\u2010Ur\u2010Rahman","sequence":"additional","affiliation":[{"name":"Health Systems and Population Studies Division icddr,b  Dhaka Bangladesh"},{"name":"College of Medicine, Nursing and Health Sciences University of Galway  Galway Ireland"},{"name":"Evidence Synthesis Ireland and Cochrane Ireland University of Galway  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,12]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Dementia.Who.int.2022. [Accessed on 10 October 2022]. Available from:https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110645"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112746"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132814"},{"key":"e_1_2_11_7_1","unstructured":"FDA Grants Accelerated Approval for Alzheimer's Drug.U.S. Food and Drug Administration.2022. [Accessed on 10 October 2022]. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.469"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101339"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S325026"},{"key":"e_1_2_11_13_1","unstructured":"Aduhelm: withdrawn application \u2010 European medicines agency. European Medicines Agency.2022. [Accessed on 10 October 2022]. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/aduhelm"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1229"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_11_18_1","unstructured":"FDA grants accelerated approval for alzheimer's disease treatment.U.S. Food and Drug Administration. FDA; [Cited 2023 January 11]. Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010grants\u2010accelerated\u2010approval\u2010alzheimers\u2010disease\u2010treatment"}],"container-title":["Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.12944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/psyg.12944","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.12944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:10:52Z","timestamp":1737407452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/psyg.12944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,12]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/psyg.12944"],"URL":"https:\/\/doi.org\/10.1111\/psyg.12944","archive":["Portico"],"relation":{},"ISSN":["1346-3500","1479-8301"],"issn-type":[{"value":"1346-3500","type":"print"},{"value":"1479-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,12]]},"assertion":[{"value":"2022-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}